Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | THRB | P10828 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472676 | 0.84 | ESR1 (0.45) | ESR1TDP1ALDH1A1THRBL3MBTL1 | |
| SCHEMBL13596292 | 0.80 | MEN1 (0.54) | ESR1L3MBTL1LMNATP53SMN1; SMN2 | |
| SCHEMBL13596299 | 0.80 | MEN1 (0.54) | ESR1L3MBTL1LMNATP53SMN1; SMN2 | |
| SCHEMBL2971862 | 0.78 | TDP1 (0.54) | ESR1TDP1ALDH1A1THRBL3MBTL1 | |
| SCHEMBL16240889 | 0.78 | ESR1 (0.56) | ESR1TDP1ALDH1A1THRBL3MBTL1 | |
| SCHEMBL6685103 | 0.76 | ESR1 (0.74) | ESR1TDP1ALDH1A1THRBCYP3A4 | |
| SCHEMBL39430 | 0.76 | TDP1 (0.72) | TDP1ALDH1A1THRBL3MBTL1CYP3A4 | |
| SCHEMBL7767529 | 0.76 | TDP1 (0.52) | TDP1ALDH1A1THRBL3MBTL1CYP3A4 | |
| SCHEMBL13233319 | 0.76 | ESR1 (0.54) | ESR1ALDH1A1THRBCYP3A4ALOX15 | |
| SCHEMBL18522799 | 0.75 | TDP1 (0.42) | TDP1ALDH1A1THRBL3MBTL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230053449-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-10815194-B2 | Process for the preparation of mono-protected α,ω-diamino alkanes | BYONDIS B.V. (NL) | 2020-10-27 | — | — | US | disclosed |
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-9988420-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-9884817-B2 | Auristatin derivatives and conjugates thereof | NOVARTIS AG (CH) | 2018-02-06 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-09-28 | — | — | US | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-9629924-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2017-04-25 | — | — | US | disclosed |
| US-8940784-B2 | Water-soluble CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2015-01-27 | — | — | US | disclosed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ESR1 4575/4885TDP1 290/4885ALDH1A1 2514/4885 |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | ESR1 4531/4885TDP1 175/4885ALDH1A1 2365/4885 |
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | ESR1 3967/4885TDP1 2762/4885ALDH1A1 3311/4885 |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ESR1 4575/4885TDP1 290/4885ALDH1A1 2514/4885 |
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | ESR1 3967/4885TDP1 2762/4885ALDH1A1 3311/4885 |
| US-20230053449-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | DCUN1D4, CD14, DCUN1D3 | ESR1 2737/4885TDP1 3961/4885ALDH1A1 2550/4885 |
| US-10815194-B2 | Process for the preparation of mono-protected α,ω-diamino alkanes | FCGRT, CD22, DEGS1 | ESR1 3221/4885TDP1 3427/4885ALDH1A1 143/4885 |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | ESR1 4468/4885TDP1 3098/4885ALDH1A1 1219/4885 |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | ESR1 4726/4885TDP1 1273/4885ALDH1A1 3212/4885 |
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | ESR1 4260/4885TDP1 741/4885ALDH1A1 1069/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ESR1 4575/4885TDP1 290/4885ALDH1A1 2514/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | ESR1 4406/4885TDP1 269/4885ALDH1A1 2235/4885 |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | ESR1 2968/4885TDP1 3796/4885ALDH1A1 1924/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ESR1 4575/4885TDP1 290/4885ALDH1A1 2514/4885 |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | ESR1 4468/4885TDP1 3098/4885ALDH1A1 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.